Consumer Biotech: The Value Chain Beneath the GLP-1 Boom | EP 234

Listen through the publisher, then discuss the episode here or arrange an in-person Roundtable. Your city determines where to meet.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
GLP-1 drugs and the peptide supply chain behind them have grown like no other drug class, reaching 44 million users within five years. Equity analyst Joshua Samuel looks past innovators Eli Lilly and Novo Nordisk to the contract manufacturers and consumables underneath them. He explains why oral GLP-1 pills can need up to 10 times more drug substance than an injection, walks through building a 39-amino-acid peptide like a LEGO set, and lays out why a silica gel supplier with about 70% global market share does not screen as a healthcare company. The conversation lands on a simple idea: growth in this market rests on several independent drivers rather than one. 0:00 - Introduction: GLP-1s Beyond the AI Trade 1:17 - Consumer Biotech: 44 Million GLP-1 Users in Five Years 2:49 - Small Molecules, Biologics, and Peptides Explained 5:01 - GLP-1 Generics, Oral Pills, and Patent Expiry 6:48 - Why Oral GLP-1 Pills Need More API 8:28 - How Peptides Are Made: The LEGO Analogy 10:56 - The Purification Bottleneck and Silica Gel 12:29 - Why Drug Approvals Lock In Suppliers 13:37 - Peptides vs. Semiconductors: Growth Drivers and Multi-Agonists 15:00 - Valuations: CDMOs vs. Consumables 19:30 - Other Healthcare Trends: Biosimilars and Small Molecule Complexity 21:53 - Outro & Subscribe GLP-1s have ramped to 44 million users within five years of Ozempic's launch, outpacing blockbuster small-molecule and biologic drugs and becoming what some now call consumer biotech. Peptide demand has moved from kilograms to tonnes. Five to seven years ago, a 100 kg API order could put a buyer in a contract manufacturer's top 10 for the year. Patent expiries and oral pills both add volume. Sandoz estimates generics could expand the market 2-7x over 5-10 years, and oral pills need 2-4x more API at Novo Nordisk and 8-10x elsewhere. Purification is the step no manufacturer can skip. Across 39 assembly steps, small yield losses compound, and once a drug is past phase two, its silica gel supplier is effectively locked in. The team owns a silica gel supplier with about 70% global share whose healthcare business is roughly 15% of sales but almost 40% of profits, and which trades like a specialty chemicals company. Beyond peptides, easier biosimilar approval is shifting work toward analytical software, and close to 70% of small molecules in development now need four to seven synthesis steps rather than two or three. Mawer employs over 250 people in Canada, U.S., and Singapore. Visit us at:
Episode information is provided by the publisher. Listening takes place on the publisher’s service.
Listen at the source ↗









